Galectin Plans To Initiate Phase 2 Clinical Trial For GR-MD-02 In Q2'15

(RTTNews) - Galectin Therapeutics Inc. (GALT) announced that the Phase 1 clinical trial of GR-MD-02 in NASH or fatty liver disease patients with advanced fibrosis met the primary endpoint. The company noted that the data from the multi-center, partially blinded Phase 1 trial showed that administration of 2, 4 and 8 mg/kg lean body weight of GR-MD-02 intravenously for four doses over 6 weeks was safe and well tolerated.

The company presented data today from Phase 1 trial at The Liver Meeting in Boston, Massachusetts.

The company said there were no serious adverse events reported in any of the three cohorts and mild (grade 1) adverse events possibly related to study drug were found in 3 placebo patients and only 2 patients receiving active drug.

Peter Traber, CEO, President and Chief Medical Officer of Galectin, said, "The company is planning to initiate a Phase 2 clinical trial in the second quarter of 2015 based on the robust pre-clinical effects of the drug and these successful Phase 1 results,"